Pharmaceutical - Newron Pharma

Filter

Current filters:

Newron Pharma

Popular Filters

Safinamide marketing application submitted to Swissmedic

07-04-2014

Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

Markets & MarketingNeurologicalNewron PharmaNorthern EuropePharmaceuticalRegulationsafinamideZambon

Patent expiries will push Parkinson’s drug market lower by 2019

17-12-2013

Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s disease (PD)…

GlobalImpax LaboratoriesMarkets & MarketingNeurologicalNewron PharmaPatentsPharmaceuticalpimavanserinRytarysafinamide

Newron and Zambon file for EU approval of Parkinson’s drug safinamide

09-12-2013

Italian drug developer Newron Pharmaceuticals and its partner, family-owned Italian drugmaker Zambon…

EuropeNeurologicalNewron PharmaNorth AmericaPharmaceuticalRegulationsafinamideZambon

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

19-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

Newron executes safinamide deal with Zambon; new Ph III data; management changes

15-05-2012

In what was a busy news day for Italian drug developer Newron Pharmaceuticals SpA (SIX: NWRN), the company…

FinancialLicensingManagementNeurologicalNewron PharmaPharmaceuticalResearchsafinamideZambon

Newron licenses safinamide to Zambon for EU and USA

09-04-2012

Italian drug developer Newron Pharmaceuticals (SIX: NWRN) says that it has signed a strategic collaboration…

LicensingMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalsafinamideZambon

Newron gets new partner for safinamide

06-01-2012

Italy-headquartered R&D firm Newron Pharmaceuticals (SIX: NWRN) yesterday revealed that it has agreed…

Asia-PacificLicensingMeiji Seika PharmaNeurologicalNewron PharmaPharmaceuticalsafinamide

Newron says it has received interest in safinamide, rejected by Merck Serono

18-11-2011

Following the announcement of Switzerland-based Newron Pharmaceuticals (SIX: NWRN) regaining the global…

LicensingNeurologicalNewron PharmaPharmaceuticalsafinamide

Repligen to buy Novozymes Biopharma Sweden business for $23 upfront; Biotie pulls out of Newron acquisition

28-10-2011

USA-based Repligen (Nasdaq: RGEN) says it has signed a definitive agreement to acquire the business of…

Biotie TherapiesMergers & AcquisitionsNewron PharmaNovozymesPharmaceuticalRepligensafinamide

Benefits of Biotie’s 45 million-euro buy of Newron assessed by Edison Research

16-10-2011

Finland-based Biotie Therapies’ (OMX: BTH1V) proposed c 45 million-euro all-stock merger with Italian…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceuticalResearch

Biotie to buy Newron for 45 million euros, creating a European leader in CNS drug development

27-09-2011

In a second acquisition this year, Finland-based biotech company Biotie Therapies (OMX: BTH1V) has entered…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceutical

Back to top